FDA warns peptide vendors selling retatrutide as a 'research' GLP-1
The FDA issued warning letters to research-peptide sellers — among them Prime Sciences and Gram Peptides — offering products labeled 'GLP-1-R', 'GLP1-S' and 'GLP1-T' that the agency identified as retatrutide, an investigational drug with no approved product that cannot lawfully be compounded. The letters cite unapproved-new-drug and misbranding violations for promoting the peptides for human use behind 'research use only' labeling, part of a broader 2026 enforcement push against GLP-1 and peptide sellers that also produced dozens of letters to telehealth firms marketing compounded GLP-1s.
Source
https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/prime-sciences-721805-03312026The issuing body’s own page is authoritative. PepIndex records what it says and when we recorded it; where the two disagree, the source governs.
Compounds affected
Ranked vendors for Retatrutide
Every vendor and price for Retatrutide →- 1
Origin Labs5 Retatrutide certificates96.9of 100Extensively documentedVisit Origin Labs - 2
Next Gen Peptides$4.00/mg listed · 16 Retatrutide certificates93.6of 100Extensively documentedVisit Next Gen Peptides - 3
Ascend Science$5.60/mg listed · 6 Retatrutide certificates91.3of 100Extensively documentedVisit Ascend Science
Ranked on this compound's price per mg against the market median, with testing and documentation counted as they are overall. A regulatory action against a vendor is recorded on that vendor's profile and counts against its score.